Italy· 045183050
GLYXAMBI*30x1 cpr rivestite 10 mg + 5 mg
A linagliptin and empagliflozin product containing empagliflozin/linagliptin, registered in Italy by BOEHRINGER INGELHEIM INT.GMBH, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Linagliptin and empagliflozin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.
- This record: Italy
- 9 of them publish a price we can compare per daily dose
Linagliptin and empagliflozin · ATC A10BD19
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Active substance
- Empagliflozin/linagliptin
- Manufacturer
- BOEHRINGER INGELHEIM INT.GMBH
- Country
- Italy (IT)
- ATC code
- A10BD19
- ATC class
- Linagliptin and empagliflozin
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic045183050GLYXAMBI*30x1 cpr rivestite 10 mg + 5 mgEUR 101.17
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A10BD19
Linagliptin and empagliflozin, as other registers publish it.
- United StatesGlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
- United StatesGlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
- FinlandGlyxambiBoehringer Ingelheim International GmbH
- DenmarkGlyxambiBoehringer Ingelheim Int. GmbH
- PolandGlyxambiBoehringer Ingelheim International GmbH
- PolandGlyxambiBoehringer Ingelheim International GmbH
- IcelandGlyxambiBoehringer Ingelheim International GmbH*
- NorwayGlyxambiBoehringer Ingelheim International GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/319d123c-09a3-48a4-944b-f4f51ebf99ca GET /v1/drugs/319d123c-09a3-48a4-944b-f4f51ebf99ca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 101.17,
"source": "aifa",
"currency": "EUR",
"strength": "EMPAGLIFLOZIN+LINAGLIPTIN 10+5MG 30 UNITA' USO ORALE",
"substance": "Empagliflozin/linagliptin",
"equivalence_group": "LAA",
"transparency_flag": null
}See everything about linagliptin and empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.